12,399 views

, 14 tweets, 2 min read

Here is the latest updates from International Organization for the Study of Inflammatory Bowel Diseases released March 26, 2020. Salient features summarized below . For full information:
ioibd.org/ioibd-update-o…

Important to know: These statements represent summation of expert opinion and should be interpreted in context of the individual patient and the managing healthcare provider who knows her or him. These are not guidelines and may be updated as knowledge and the situation evolve.

1- It is uncertain if active inflammation from IBD increases the risk of getting SARS-CoV-2.
2-It is uncertain if patients with IBD who develop COVID-19 have a higher mortality compared to patients without IBD.

3-It is safe to continue infusions in an infusion center, assuming the infusion center has a screening protocol in place ( Now this is important and you may want to check it out with your infusion place)

4-Patients taking budesonide therapy should not reduce the dose of therapy to prevent SARS-CoV-2 infection.
5-Patients taking prednisone therapy (≥20mg/d) should reduce the dose of therapy to prevent SARS-CoV-2 infection.

6- Patients taking azathioprine/6-MP, MTX, anti TNF, Vedo should not reduce/discontinue the dose of therapy to prevent SARS-CoV-2 infection

7-Patients taking azathioprine/6-azathioprine/6-MP, MTX should stop therapy if they test positive for SARS-CoV-2 but don’t have COVID-19
8-It is uncertain if patients taking anti-TNF, UST Vedo therapy should stop therapy if they test positive for SARS-CoV-2 but don’t have COVID

9-Patients taking AZA, 6MP, MTX, UST, anti-TNF therapy should stop therapy if they develop COVID-19
10-It is uncertain if patients taking vedolizumab should stop therapy if they develop COVID-19

9-Patients taking tofacitinib should stop therapy if they test positive for SARS-CoV-2 but don’t have COVID-19.
10-It is uncertain if patients taking combination therapy with anti-TNF+ thiopurine/MTX should reduce the dose of the thiopurine/MTX to prevent infection

10-Patients taking clinical trial drugs should not discontinue therapy to prevent SARS-CoV-2 infection.
Patients taking clinical trial drugs should stop therapy if they test positive for SARS-CoV-2

11- In IBD patient who tests positive for SARS-CoV-2 and whose IBD meds have been stopped because of this, IBD meds can be restarted after 14 days (provided they have not developed COVID-19)

12- In IBD patient who develops COVID-19 and whose IBD meds have been stopped, IBD meds can be restarted after COVID-19 symptoms resolve

13-In IBD patient who develops COVID-19 and whose IBD meds have been stopped, IBD meds can be restarted after 2 nasopharyngeal PCR tests are negative.